tbuckley/cabot-search huggingface dataset:
Biodegradable stents developed
Authors: Deborah Josefson
Journal: BMJ (2000)

Biodegradable arterial stents may offer advantages over metallic ones in coronary artery angioplasty. Researchers, led by Drs Hideo Tamai from Shiga Medical Center, and Keiji Igaki from Igaki Medical Planning, Japan, tested biodegradable coronary artery stents in 15 patients and have shown for the first time that the use of such stents is both feasible and safe. ( Circulation 2000;102:371-3, 399-404).

Twenty five …
Perfusion of a Strip of Mammalian Ventricle
Authors: JEAN DÉLEZE
Journal: Circulation Research (1959)

A preparation of sheep's or calf's myocardium is described: the m. transversus cordis of the right ventricle. This lends itself to perfusion of its capillary bed as well as to the recording of membrane potentials from single fibers. When the Na concentration in the perfusate is reduced, the action potentials undergo changes that suggest that the "sodium hypothesis" is applicable to cardiac ventricle.
Histological assessment of the early enthesitis lesion in spondyloarthropathy
Authors: D McGonagle
Journal: Annals of the Rheumatic Diseases (2002)

Objectives: To describe the histological changes in acute enthesopathy in early spondyloarthropathies (SpA). Methods: Clinically evident acute enthesopathy was confirmed by magnetic resonance imaging and ultrasonography in four cases of plantar fasciitis and one case of patellar tendon enthesitis. Ultrasound guided biopsy of insertional points was carried out with a Jamshedi needle. Control tissue was obtained from two subjects undergoing spinal grafting surgery. Standard histochemistry and immunohistochemistry analysis using the avidin-biotin immunoperoxidase complex method employing markers against CD3, CD8, CD34, and CD68 was used to determine cellular infiltrates at the insertion point. Results: The enthesis architecture was abnormal in the SpA group, with increased vascularity and cellular infiltration compared with normal subjects. The predominant infiltrating cell at the enthesis fibrocartilage was the macrophage, but there was a paucity of lymphocytes at the insertion point. Conclusion: These preliminary findings have implications for a better understanding of the pathology in early SpA.
A 4‐yr‐old presenting with chronic cough and asymmetrical chest
Authors: A.V. Sridhar, M. Tofeig
Journal: European Respiratory Journal (2003)

A 4‐yr‐old female was referred by her general practitioner with history of recurrent cough of 18 months duration. The cough was predominantly nocturnal with no associated wheeze, fever or systemic symptoms and no symptoms of gastro-oesophageal reflux. There were no exercise-induced symptoms. Asthma was suspected and she had been treated with inhaled salbutamol with no significant improvement in her symptoms. There was no history of recurrent chest infections, foreign body aspiration or previous hospital admissions.

On examination her weight was on the 3rd centile and height on the 50th centile. There were no cyanosis, clubbing or ear, nose and throat abnormalities. She had a markedly asymmetrical chest with less prominent right hemithorax compared with the left and mediastinal shift to the right. Breath sounds were diminished on the right side with no wheeze or crepitations. The rest of the cardiovascular examination was normal. There were no other abnormalities on clinical examination.

In view of her chronic cough and failure to thrive she had a mantoux test, which was strongly positive. She had bacille Calmette-Guerin vaccination at birth and there was no recent contact with tuberculosis (TB). The sputum was negative for Mycobacterium tuberculosis . She was given TBB chemoprophylaxis with Isoniazid and Rifampicin for 6 months, during which she had a symptomatic improvement in her cough.

A chest radiograph (fig. 1⇓) and computed tomography (CT) scan of the thorax (fig. 2⇓) revealed characteristic findings.



Fig. 1.— 
Chest radiograph of …
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile
Authors: Tuomas O Kilpeläinen, M Carola Zillikens, Alena Stančákova, Francis M Finucane, Janina S Ried, Claudia Langenberg, Weihua Zhang, Jacques S Beckmann, Jian'an Luan, Liesbeth Vandenput, Unnur Styrkarsdottir, Yanhua Zhou, Albert Vernon Smith, Jing-Hua Zhao, Najaf Amin, Sailaja Vedantam, So-Youn Shin, Talin Haritunians, Mao Fu, Mary F Feitosa, Meena Kumari, Bjarni V Halldorsson, Emmi Tikkanen, Massimo Mangino, Caroline Hayward, Ci Song, Alice M Arnold, Yurii S Aulchenko, Ben A Oostra, Harry Campbell, L Adrienne Cupples, Kathryn E Davis, Angela Döring, Gudny Eiriksdottir, Karol Estrada, José Manuel Fernández-Real, Melissa Garcia, Christian Gieger, Nicole L Glazer, Candace Guiducci, Albert Hofman, Steve E Humphries, Bo Isomaa, Leonie C Jacobs, Antti Jula, David Karasik, Magnus K Karlsson, Kay-Tee Khaw, Lauren J Kim, Mika Kivimäki, Norman Klopp, Brigitte Kühnel, Johanna Kuusisto, Yongmei Liu, Östen Ljunggren, Mattias Lorentzon, Robert N Luben, Barbara McKnight, Dan Mellström, Braxton D Mitchell, Vincent Mooser, José Maria Moreno, Satu Männistö, Jeffery R O'Connell, Laura Pascoe, Leena Peltonen, Belén Peral, Markus Perola, Bruce M Psaty, Veikko Salomaa, David B Savage, Robert K Semple, Tatjana Skaric-Juric, Gunnar Sigurdsson, Kijoung S Song, Timothy D Spector, Ann-Christine Syvänen, Philippa J Talmud, Gudmar Thorleifsson, Unnur Thorsteinsdottir, André G Uitterlinden, Cornelia M van Duijn, Antonio Vidal-Puig, Sarah H Wild, Alan F Wright, Deborah J Clegg, Eric Schadt, James F Wilson, Igor Rudan, Samuli Ripatti, Ingrid B Borecki, Alan R Shuldiner, Erik Ingelsson, John-Olov Jansson, Robert C Kaplan, Vilmundur Gudnason, Tamara B Harris, Leif Groop, Douglas P Kiel, Fernando Rivadeneira, Mark Walker, Inês Barroso, Peter Vollenweider, Gérard Waeber, John C Chambers, Jaspal S Kooner, Nicole Soranzo, Joel N Hirschhorn, Kari Stefansson, H-Erich Wichmann, Claes Ohlsson, Stephen O'Rahilly, Nicholas J Wareham, Elizabeth K Speliotes, Caroline S Fox, Markku Laakso, Ruth J F Loos
Journal: Nature Genetics (2011)
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
Authors: J.F. Vansteenkiste, J.E. Vandebroek, K.L. Nackaerts, P. Weynants, Y.J. Valcke, D.A. Verresen, R.C. Devogelaere, S.A. Marien, Y.P. Humblet, N.L. Dams
Journal: Annals of Oncology (2001)
Dermatomyositis complicating penicillamine treatment.
Authors: L Fernandes, D R Swinson, E B Hamilton
Journal: Annals of the Rheumatic Diseases (1977)

A case of dermatomyositis developing during the course of treatment with D-penicillamine in a patient with rheumatoid arthritis is described. Complete remission occurred on withdrawal of the drug. Possible alternative diagnoses are discussed.
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
Authors: David R. Spigel, Peter M. Townley, David M. Waterhouse, Liang Fang, Ibrahim Adiguzel, Jane E. Huang, David A. Karlin, Leonardo Faoro, Frank A. Scappaticci, Mark A. Socinski
Journal: Journal of Clinical Oncology (2011)

Purpose Because of promising efficacy signals in single-arm studies, a placebo-controlled, double-blind, randomized phase II trial was designed to assess the efficacy and safety of adding bevacizumab to first-line standard chemotherapy for treatment of extensive-stage small-cell lung cancer (SCLC). Patients and Methods Patients with SCLC were randomly assigned to receive bevacizumab or placebo, with cisplatin or carboplatin plus etoposide, for four cycles followed by single-agent bevacizumab or placebo until progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Results Fifty-two patients were randomly assigned to the bevacizumab group and 50 to the placebo group; 69% versus 66%, respectively, completed four cycles of therapy. Median PFS was higher in the bevacizumab group (5.5 months) than in the placebo group (4.4 months; hazard ratio [HR], 0.53; 95% CI, 0.32 to 0.86). Median overall survival (OS) was similar for both groups (9.4 v 10.9 months for bevacizumab and placebo groups, respectively), with an HR of 1.16 (95% CI, 0.66 to 2.04). Overall response rates were 58% (95% CI, 43% to 71%) for the bevacizumab group and 48% (95% CI, 34% to 62%) for the placebo group. Median duration of response was 4.7 months for the bevacizumab group and 3.2 months for the placebo group. In the bevacizumab and placebo groups, 75% versus 60% of patients, respectively, experienced one or more grade 3 or higher adverse events. No new or unexpected safety signals for bevacizumab were observed. Conclusion The addition of bevacizumab to cisplatin or carboplatin plus etoposide for treatment of extensive-stage SCLC improved PFS, with an acceptable toxicity profile. However, no improvement in OS was observed.
Arterial embolization caused by injection of hyaluronic acid (RestylaneR)
Authors: S. Schanz, W. Schippert, A. Ulmer, G. Rassner, G. Fierlbeck
Journal: British Journal of Dermatology (2002)

Journal Article Arterial embolization caused by injection of hyaluronic acid (Restylane®) Get access S. Schanz, S. Schanz Department of Dermatology, University Hospital Tübingen, Liebermeisterstraße 25, D‐72076 Tübingen, Germany Search for other works by this author on: Oxford Academic Google Scholar W. Schippert, W. Schippert Department of Dermatology, University Hospital Tübingen, Liebermeisterstraße 25, D‐72076 Tübingen, Germany Search for other works by this author on: Oxford Academic Google Scholar A. Ulmer, A. Ulmer Department of Dermatology, University Hospital Tübingen, Liebermeisterstraße 25, D‐72076 Tübingen, Germany Search for other works by this author on: Oxford Academic Google Scholar G. Rassner, G. Rassner Department of Dermatology, University Hospital Tübingen, Liebermeisterstraße 25, D‐72076 Tübingen, Germany Search for other works by this author on: Oxford Academic Google Scholar G. Fierlbeck G. Fierlbeck Department of Dermatology, University Hospital Tübingen, Liebermeisterstraße 25, D‐72076 Tübingen, Germany Correspondence: Prof. Dr Gerhard Fierlbeck. E‐mail: gerhard.fierlbeck@med.uni‐tuebingen.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 146, Issue 5, 1 May 2002, Pages 928–929, https://doi.org/10.1046/j.1365-2133.2002.04707.x Published: 01 May 2002
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
Authors: Roberto Piva, Roberto Chiarle, Andrea D. Manazza, Riccardo Taulli, William Simmons, Chiara Ambrogio, Valentina D'Escamard, Elisa Pellegrino, Carola Ponzetto, Giorgio Palestro, Giorgio Inghirami
Journal: Blood (2005)
Arrested natural killer cell development associated with transgene insertion into the Atf2 locus
Authors: Sungjin Kim, Yun-Jeong Song, Darryl A. Higuchi, Hyunseok P. Kang, Jennifer R. Pratt, Liping Yang, Caron M. Hong, Jennifer Poursine-Laurent, Koho Iizuka, Anthony R. French, John B. Sunwoo, Shunsuke Ishii, Andreas M. Reimold, Wayne M. Yokoyama
Journal: Blood (2005)
BREATHING DEFICIT, ALLERGY, AND ALCOHOLISM
Authors: NORMAN G. HAWKINS
Journal: American Journal of Psychiatry (1958)

Cases of alcoholic tuberculosis patients presented some instances of a history of physical complaints which gave rise to the hypothesis that respiratory defects and allergy are associated with alcoholism. The hypothesis was investigated in a random sample of discharged cases from Firland Sanatorium in Seattle, numbering 100 and evenly divided by sex and with reference to alcoholic diagnosis. Alcoholics were significantly distinguished by one or more of a selected list of respiratory complaints, by a multiplicity of them, by the more individually frequent of them, and by gastrointestinal and skin allergies. Respiratory complaints and allergies were associated among alcoholics and nonalcoholics alike, particularly sinusitis. Assuming these findings to be valid for at least some alcoholics, a theoretical explanation is suggested. Respiratory difficulty and anxiety are mutually and cumulatively interrelated in causative fashion. Both are relieved by the use of alcohol. Acquiring this sort of relief from a chronic condition gradually takes precedence over a widening range of activities.
Involvement of Chemokine Receptor 4/Stromal Cell–Derived Factor 1 System during Osteosarcoma Tumor Progression
Authors: Eliana Perissinotto, Giuliana Cavalloni, Francesco Leone, Valentina Fonsato, Stefania Mitola, Giovanni Grignani, Nadia Surrenti, Dario Sangiolo, Federico Bussolino, Wanda Piacibello, Massimo Aglietta
Journal: Clinical Cancer Research (2005)

Abstract Despite intensive chemotherapy and surgery treatment, lung and bone metastasis develop in about 30% of patients with osteosarcoma. Mechanisms for this preferential metastatic behavior are largely unknown. We investigated the role of the chemokine receptor 4 (CXCR4)/stromal cell–derived factor 1 (SDF-1) system to drive the homing of osteosarcoma cells. We analyzed the expression of the CXCR4 and SDF-1 proteins on several osteosarcoma cell lines and the effects of SDF-1 on migration, adhesion, and proliferation of these cancer cells. In vitro assays showed that the migration of osteosarcoma cells expressing CXCR4 receptor follows an SDF-1 gradient and that their adhesion to endothelial and bone marrow stromal cells is promoted by SDF-1 treatment. Moreover, the production of matrix metalloproteinase-9 is increased after SDF-1 exposure. We finally proved in a mouse model our hypothesis of the CXCR4/SDF-1 axis involvement in the metastatic process of osteosarcoma cells. Development of lung metastasis after injection of osteosarcoma cells was prevented by the administration of a CXCR4 inhibitor, the T134 peptide. These data show a possible explanation for the preferential osteosarcoma metastatic development into the lung, where SDF-1 concentration is high, and suggest that molecular strategies aimed at inhibiting the CXCR4/SDF-1 pathway, such as small-molecule inhibitors or anti-CXCR4 antibodies, might prevent the dissemination of osteosarcoma cells.
Vascular Proliferation and Enhanced Expression of Endothelial Nitric Oxide Synthase in Human Peritoneum Exposed to Long-Term Peritoneal Dialysis
Authors: SOPHIE COMBET, TOSHIO MIYATA, PIERRE MOULIN, DOMINIQUE POUTHIER, ERIC GOFFIN, OLIVIER DEVUYST
Journal: Journal of the American Society of Nephrology (2000)

Abstract. Long-term peritoneal dialysis (PD) is associated with alterations in peritoneal permeability and loss of ultrafiltration. These changes originate from increased peritoneal surface area, but the morphologic and molecular mechanisms involved remain unknown. The hypothesis that modifications of activity and/or expression of nitric oxide synthase (NOS) isozymes might play a role in these modifications, via enhanced local production of nitric oxide, was tested in this study. NOS activities were measured by the L-citrulline assay in peritoneal biopsies from seven control subjects, eight uremic patients immediately before the onset of PD, and 13 uremic patients on short-term (&lt;18 mo, n = 6) or long-term (&gt;18 mo, n = 7) PD. Peritoneal NOS activity is increased fivefold in long-term PD patients compared with control subjects. In uremic patients, NOS activity is positively correlated with the duration of PD. Increased NOS activity is mediated solely by Ca 2+ -dependent NOS and, as shown by immunoblotting, an upregulation of endothelial NOS. The biologic relevance of increased NOS in long-term PD was demonstrated by enhanced nitrotyrosine immunoreactivity and a significant increase in vascular density and endothelial area in the peritoneum. Immunoblotting and immunostaining studies demonstrated an upregulation of vascular endothelial growth factor (VEGF) mostly along the endothelium lining peritoneal blood vessels in long-term PD patients. In the latter, VEGF colocalized with the advanced glycation end product pentosidine deposits. These data provide a morphologic (angiogenesis and increased endothelial area) and molecular (enhanced NOS activity and endothelial NOS upregulation) basis for explaining the permeability changes observed in long-term PD. They also support the implication of local advanced glycation end product deposits and liberation of VEGF in that process.
Effects of a task-specific warm-up on anaerobic power.
Authors: J A Hawley, M M Williams, G C Hamling, R M Walsh
Journal: British Journal of Sports Medicine (1989)

Twenty-four untrained (UT) males (age 21 +/- 2.5 yr, height 1.77 +/- 0.05 m, weight 75.3 +/- 10.1 kg, values mean +/- SD) performed the Wingate Anaerobic Test (WT) under two conditions, cold (C) and following a warm-up (WU). Trials were separated by a minimum of 48 h. A modified Monark 818 cycle ergometer was interfaced with an Apple IIE microcomputer and peak power (PEAK), mean power (MEAN) and fatigue index (FI) determined. The WU trial consisted of an 8 min incremental continuous cycling bout (cadence 90 rev.min-1) with 5 min rest before the WT. During the C trial subjects completed only the WT. A repeated measures design was employed with order of trials counterbalanced. ANOVA revealed no significant differences for PEAK or MEAN between WU or C conditions. However FI was significantly greater (p less than 0.05) following the WU. A significant correlation (r = 0.45, p = 0.03) was obtained between WU intensity and FI. These findings suggest that our UT subjects were fatiguing themselves during the WU. Future studies are needed to assess whether a task-specific WU in which FI is not impaired would lead to improvements in PEAK and MEAN. Investigators should be aware that a self-spaced WU may increase FI in the WT in UT subjects.
Long-term risk of colorectal cancer in individuals with serrated polyps
Authors: Øyvind Holme, Michael Bretthauer, Tor J Eide, Else Marit Løberg, Krzysztof Grzyb, Magnus Løberg, Mette Kalager, Hans-Olov Adami, Øystein Kjellevold, Geir Hoff
Journal: Gut (2014)

<h3>Objective</h3> Although serrated polyps may be precursors of colorectal cancer (CRC), prospective data on the long-term CRC risk in individuals with serrated polyps are lacking. <h3>Design</h3> In a population-based randomised trial, 12 955 individuals aged 50–64 years were screened with flexible sigmoidoscopy, while 78 220 individuals comprised the control arm. We used Cox models to estimate HRs with 95% CIs for CRC among individuals with ≥1 large serrated polyp (≥10 mm in diameter), compared with individuals with adenomas at screening, and to population controls, and multivariate logistic regression to assess polyp risk factors for CRC. <h3>Results</h3> A total of 103 individuals had large serrated polyps, of which 81 were included in the analyses. Non-advanced adenomas were found in 1488 individuals, advanced adenomas in 701. Median follow-up was 10.9 years. Compared with the control arm, the HR for CRC was 2.5 (95% CI 0.8 to 7.8) in individuals with large serrated polyps, 2.0 (95% CI 1.3 to 2.9) in individuals with advanced adenomas and 0.6 (95% CI 0.4 to 1.1) in individuals with non-advanced adenomas. A large serrated polyp was an independent risk factor for CRC, adjusted for histology, size and multiplicity of concomitant adenomas (OR 3.3; 95% CI 1.3 to 8.6). Twenty-three large serrated polyps found at screening were left in situ for a median of 11.0 years. None developed into a malignant tumour. <h3>Conclusions</h3> Individuals with large serrated polyps have an increased risk of CRC, comparable with individuals with advanced adenomas. However, this risk may not be related to malignant growth of the serrated polyp. <h3>Trial registration number</h3> The Norwegian Colorectal Cancer Screening trial is registered at clinicaltrials.gov (NCT00119912).
Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile
Authors: Gordon J. Gaschler, Marko Skrtic, Caleb C. J. Zavitz, Maria Lindahl, Per-Ola Onnervik, Timothy F. Murphy, Sanjay Sethi, Martin R. Stämpfli
Journal: American Journal of Respiratory and Critical Care Medicine (2009)

Rationale: The pathogenesis of chronic obstructive pulmonary disease is associated with acute episodes of bacterial exacerbations. The most commonly isolated bacteria during episodes of exacerbation is nontypeable Haemophilus influenzae (NTHI).Objectives: In this study, we investigated the in vivo consequences of cigarette smoke exposure on the inflammatory response to an NTHI challenge.Methods: C57BL/6 and BALB/c mice were exposed to cigarette smoke for 8 weeks and subsequently challenged intranasally with NTHI.Measurements and Main Results: We observed increased pulmonary inflammation and lung damage in cigarette smoke–exposed NTHI-challenged mice as compared with control NTHI-challenged mice. Furthermore, although NTHI challenge in control mice was marked by increases in tumor necrosis factor-α, IL-6, MIP-2, and KC/GROα, NTHI challenge in cigarette smoke–exposed mice led to a prominent up-regulation of a different subset of inflammatory mediators, most notably MCP-1, -3, and -5, IP-10, and MIP-1γ. This skewed inflammatory mediator expression was also observed after ex vivo NTHI stimulation of alveolar macrophages, signifying their importance to this altered response. Importantly, corticosteroids attenuated inflammation after NTHI challenge in both cigarette smoke–exposed and control mice; however, this was associated with significantly increased bacterial burden.Conclusions: Collectively, these data suggest that cigarette smoke exacerbates the inflammatory response to a bacterial challenge via skewed inflammatory mediator expression.